<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">David M. Holtzman</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>Washington University in St. Louis</td>
</tr>
<tr>
<td class="label">Country</td>
<td>USA</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>200</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0001-6390-095X" target="_blank">0000-0001-6390-095X</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers)</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>[Amyloid](/mechanisms/amyloid-cascade), [APOE](/mechanisms/apoe-ad), [Sleep](/mechanisms/sleep-disruption-ad)</td>
</tr>
</table>
David M. Holtzman
Overview
David M. Holtzman is a leading researcher in the field of neurodegenerative diseases, affiliated with Washington University in St. Louis. Their research focuses on Amyloid, [APOE](/genes/apoe), Sleep, with particular emphasis on [Alzheimer's Disease](/diseases/alzheimers-disease). With an h-index of 200, Holtzman is among the most cited researchers in the neuroscience field[@orcid2026].
...<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">David M. Holtzman</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>Washington University in St. Louis</td>
</tr>
<tr>
<td class="label">Country</td>
<td>USA</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>200</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0001-6390-095X" target="_blank">0000-0001-6390-095X</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers)</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>[Amyloid](/mechanisms/amyloid-cascade), [APOE](/mechanisms/apoe-ad), [Sleep](/mechanisms/sleep-disruption-ad)</td>
</tr>
</table>
David M. Holtzman
Overview
David M. Holtzman is a leading researcher in the field of neurodegenerative diseases, affiliated with Washington University in St. Louis. Their research focuses on Amyloid, [APOE](/genes/apoe), Sleep, with particular emphasis on [Alzheimer's Disease](/diseases/alzheimers-disease). With an h-index of 200, Holtzman is among the most cited researchers in the neuroscience field[@orcid2026].
Holtzman's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Alzheimer's Disease. Their research group has made significant contributions to the fields of Amyloid, APOE, Sleep, publishing in high-impact journals including Nat Rev Neurol.
Based at Washington University in St. Louis, Holtzman collaborates with researchers across multiple institutions worldwide, working to advance therapeutic strategies for neurodegenerative conditions.
Research Focus
Disease Areas
- [Alzheimer's Disease](/diseases/alzheimers-disease)
Mechanisms of Interest
- [Amyloid](/mechanisms/amyloid-cascade)
- [APOE](/genes/apoe)
- [Sleep](/mechanisms/sleep-disruption-ad)
Programmatic Emphasis
Holtzman's portfolio emphasizes mechanism-aware biomarker interpretation and translational hypothesis testing in Alzheimer's Disease[@long2019]. Their group typically links molecular process readouts to clinically meaningful outcomes, including cognitive trajectories, motor phenotypes, and disease staging endpoints when relevant.
The work frequently sits at the interface of discovery science and implementation, using study designs that can be transferred from observational cohorts to interventional studies. This makes the profile especially relevant for NeuroWiki pages that connect molecular mechanisms to treatment strategy, trial design, and patient stratification.
Methods and Data Strategy
Within the Amyloid, APOE, Sleep domain, this research profile is most aligned with multimodal integration: combining imaging, biofluid, genomic, and clinical metadata to derive robust disease signatures. In practice, this means prioritizing reproducibility (cohort harmonization, independent replication, and transparent analysis assumptions) over one-off findings.
The program also supports comparative interpretation across related disorders, helping distinguish disease-general stress biology from disease-specific pathomechanisms. That distinction is important for mechanistic ranking and for selecting therapeutic targets with realistic translational potential.
Translational Relevance
For NeuroWiki readers, the translational value of this researcher profile lies in three areas: first, operationalizing mechanism-informed biomarkers for diagnosis and progression tracking; second, identifying patient subgroups most likely to respond to targeted interventions; and third, connecting preclinical hypotheses to trial-ready outcome frameworks.
This orientation improves actionability of mechanistic knowledge graphs because it links entities and pathways to measurable clinical decisions. Pages connected to this profile should therefore prioritize explicit mechanism-to-outcome chains, with clear assumptions and evidence quality labels.
Key Publications
[APOE and Alzheimer's disease](https://doi.org/10.1038/nrneurol.2015.65). Nat Rev Neurol, 2015.[@apoe2015]
Recent Research
Recent PubMed-indexed publications (2024-present):
[Sex-specific genetic regulation of proteomics in cerebrospinal fluid uncovers genetic causes for sex differences in neurodegeneration.](https://pubmed.ncbi.nlm.nih.gov/41282806/). medRxiv : the preprint server for health sciences. 2025.
[Dynamic proportional loss of functional connectivity revealed change of left superior frontal gyrus in subjective cognitive decline: an explanatory study based on Chinese and Western cohorts.](https://pubmed.ncbi.nlm.nih.gov/39888585/). GeroScience. 2025.
[GWAS meta-analysis of CSF Alzheimer's disease biomarkers 18,948 individuals reveal novel loci and genes regulating lipid metabolism, brain volume and autophagy.](https://pubmed.ncbi.nlm.nih.gov/40470240/). Research square. 2025.
[Large-scale Plasma Proteomic Profiling Unveils Novel Diagnostic Biomarkers and Pathways for Alzheimer's Disease.](https://pubmed.ncbi.nlm.nih.gov/40166037/). Research square. 2025.
Collaborators and Research Network
[Lennart Mucke](/researchers/lennart-mucke), [Dennis J. Selkoe](/researchers/dennis-selkoe), [Kristine Yaffe](/researchers/kristine-yaffe), [John H. Morrison](/researchers/john-morrison)
Institutional Context
Primary institutional links: [Washington University in St. Louis](/washington-university-in-st.-louis). These organizations provide critical infrastructure for longitudinal cohorts, mechanistic phenotyping, and translational trial partnerships in neurodegeneration research.
Open Questions and Future Directions
- How can Amyloid, APOE, Sleep signals be standardized across cohorts and sites without losing disease-stage sensitivity?
- Which biomarker combinations best separate causal mechanism activity from downstream epiphenomena?
- What trial designs can most efficiently translate mechanistic findings in Alzheimer's Disease into clinically meaningful interventions?
External Links
- ORCID: [https://orcid.org/0000-0001-6390-095X](https://orcid.org/0000-0001-6390-095X)
- Google Scholar: [Search for David M. Holtzman](https://scholar.google.com/scholar?q=author%3A%22David+M.+Holtzman%22)
- PubMed: [Author search for David M. Holtzman](https://pubmed.ncbi.nlm.nih.gov/?term=David+M.+Holtzman%5BAuthor%5D)
See Also
- [Researchers and Institutions Index](/researchers)
- [Diseases Index](/diseases)
- [Mechanisms Index](/mechanisms)
References
[Unknown, APOE and Alzheimer's disease (2015)](https://doi.org/10.1038/nrneurol.2015.65)
Unknown, ORCID profile for David M. Holtzman (2026)
[Unknown, Long and Holtzman, Alzheimer disease an update on pathobiology and treatment strategies 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/30617256/)